The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: A first in class epothilone B analogue in late-phase clinical development

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2701-2709

  Goel, Sanjay ^a   Cohen, Marvin ^b   Çömezoglu, S Nilgün ^b   Perrin, Lionel ^c   André, François ^c   Jayabalan, David ^a   Lacono, Lisa ^b   Comprelli, Adriana ^b   Ly, Van T ^b   Zhang, Donglu ^b   Xu, Carrie ^b   Humphreys, W Griffith ^b   McDaid, Hayley ^a   Goldberg, Gary ^a   Horwitz, Susan B ^a   Mani, Sridhar ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A4; EPOTHILONE B; FURAFYLLINE; IXABEPILONE; KETOCONAZOLE; MONTELUKAST; NORMEPHENYTOIN; QUINIDINE; SULFAPHENAZOLE; TRANYLCYPROMINE; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; EPOTHILONE DERIVATIVE; TUBULIN MODULATOR;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; ENDOMETRIUM CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MICROTUBULE; MOLECULAR MODEL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SIDE EFFECT; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; BIOLOGY; DRUG ANTAGONISM; FEMALE GENITAL TRACT TUMOR; LIVER; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MONONUCLEAR CELL; NEOPLASM; PROSTATE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; CYTOCHROME P-450 CYP3A; EPOTHILONES; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; KETOCONAZOLE; LEUKOCYTES, MONONUCLEAR; LIVER; LIVER NEOPLASMS; MALE; MICROSOMES, LIVER; MIDDLE AGED; NEOPLASMS; PROSTATIC NEOPLASMS; TUBULIN MODULATORS;

EID: 52049120147     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4151     Document Type: Article

References (44)

1. Mani S, Macapinlac M, Jr., Goel S, et al. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 2004;15:553-8.
2. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-98.
3. McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002;8: 2035-43.
4. Zhuang SH, Agrawal M, Edgerly M, et al. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932-8.
5. Aghajanian C, Burris HA III, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25: 1082-8.
6. AmritaVK, Ming C, Francis YL.Yueping Z, Punit HM. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother Pharmacol 2005;V56:145.
7. Williams PA, Cosme J, Vinkovic DM, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004;305: 683-6.
8. Marechal JD, Yu J, Brown S, et al. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab Dispos 2006;34:534-8.
9. Zhou D, Afzelius L, Grimm SW, Andersson TB, Zauhar RJ, Zamora I. Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab Dispos 2006;34:976-83.
10. Goel S, Goldberg G, lacono L, et al. Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone. Proc Am Soc Clin Oncol 2006;24:435.
11. 14C- ixabepilone in mouse, rat, dog, monkey and human liver microsomes. Drug Metabol Rev 2006; 38:173.
12. Gelboin HV, Krausz K. Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm. J Clin Pharmacol 2006;46:353-72.
13. Mani S, McDaid HM, Grossman A, et al. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol 2007;18:190-5.
14. Denduluri N, Lee J J, Walshe J, et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007:25:3421-7.
15. Whitehead RP, McCoy S, Rivkin SE, et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 2006;24:515-20.
16. Ajani JA, Safran H, Bokemeyer C, et al. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 2006;24:441-6.
17. Hussain M,Tangen CM, Lara PN, Jr., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724-9.
18. Gadgeel SM,Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005;11:6233-9.
19. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34.
20. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46.
21. Smaletz O, Galsky M, Scher HI, et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003:14:1518-24.
22. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866-73.
23. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37.
24. Beumer JH, Garner RC, Cohen MB, et al. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs 2007;25:327-34.
25. Isin EM, Guengerich FP. Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 2006;281:9127-36.
26. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002;30: 438-45.
27. Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J. Drug interactions of paclitaxel metabolism in human liver microsomes. J Chemother 2003;15:266-74.
28. Jamis-Dow CA. Klecker RW, Katki AG, Collins JM. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995;36:107-14.
29. Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. Am J Clin Oncol 1997; 20:592-9.
30. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006; 57:685-92.
31. Zhu H RA, Cohen M, Pfister M. Exposure-response analysis for ixabepilone associated neutropenia. Clin Pharmacol Ther 2007;81:S121-8.
32. Huang H,Wang H, Sinz M, et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007;26: 258-68.
33. Takeshita A, Taguchi M, Koibuchi N, OzawaY. Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 2002;277:32453-8.
34. Duret C, Daujat-Chavanieu M, Pascussi JM, et al. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol 2006;70:329-39.
35. Mensah-Osman EJ,Thomas DG,Tabb MM, et al. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer 2007;109:957-65.
36. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, SegawaT, Hiramatsu Y. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol 2005;19:1170-80.
37. Mani S, Huang H, Sundarababu S, et al. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res 2005;11:6359 - 69.
38. Takami N, Sakamoto H,YamamotoT. Steroid and xenobiotic receptor (SXR) is a key system for the acquisition of cisplatin resistance in endometrial cancer cells. J Int Med Res 2003;31:59-68.
39. Giuliano KA. High-content profiling of drug-drug interactions: cellular targets involved in the modulation of microtubule drug action by the antifungal ketoconazole. J Biomol Screen 2003;8:125-35.
40. Wang YJ,Yu CF, Chen LC, et al. Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. J Cell Biochem 2002;87:147-59.
41. Martinez C, Garcia-Martin E, Pizarro RM, Garcia-Gamito FJ, Agundez JA. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 2002:87:681 -6.
42. 1 arrest in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol 2000:169:132-41.
43. Wang YJ, Jeng JH, Chen RJ, et al. Ketoconazole potentiates the antitumor effects of nocodazole: in vivo therapy for human tumor xenografts in nude mice. Mol Carcinog 2002;34:199-210.
44. Ho YS, Tsai PW, Yu CF, Liu HL, Chen RJ, Lin JK. Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines. J Cell Biochem 2002;87: 147-59.